Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (14247)	11/20/2004 1:54:31 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Ken: You asked Miljenko. I'll answer, but certainly to not know what his answer might be. Bob Oldham's BioTherapeutics (Memphis, Franklin) was the first "personalized medicine" biotech. I owned some shares, maybe 1987?? (!!). Company went poof (with Ed Lamphier as V.P. Business Development, btw). They couldn't raise enough bucks to continue on the "personalized medicine" track, and no company has made it since. Margins for a "one size fits all" pharmaceutical are usually better than 90%. For personalized medicine, margins have proven to be 0% until the effort fails. It's proven to be wise course..... wait until and if the business plan matures, and the company proves that it can turn that "margin" corner. I was a frequent visitor to Franklin and Memphis at the time, as I worked for a (crappy) company that was engaged in a Medarex-like project with BioTherapeutics. We were constructing bispecific monoclonals, one arm of which was anticipated to target "a cancer" while the other arm, anti-CD1, was intended to non-specifically stimulate (and recruit) cytotoxic T cells. Everything in biotech is new, with the exception of cancer immunology companies. There, the concepts are reborn, reborn, and reborn again. The only link that I could find which might be of interest..... aidsinfobbs.org edit: here's another link that might be fun...... the-scientist.com and here's a bit of flavor..... ncbi.nlm.nih.gov Rick